|Day's Range||29.36 - 29.49|
|52 Week Range||26.11 - 29.95|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.70%|
The overall contribution of Novartis's (NVS) Innovative Medicines segment is ~67.0% of its total revenues.
The sector has seen the weakest growth in its top and bottom lines due to uncertainty in terms of sector reforms.
Qualcomm (QCOM) recorded a year-over-year decline in revenues for 2Q17 after growth in the preceding quarter.